Canaccord Genuity Initiates Coverage On Achieve Life Sciences with Buy Rating, Announces Price Target of $13

Benzinga Newsdesk www.benzinga.com Neutral 58.0%

Neg 0% Neu 58% Pos 0%

Canaccord Genuity analyst Gary Nachman initiates coverage on Achieve Life Sciences (NASDAQ:ACHV) with a Buy rating and announces Price Target of $13.